SNDX Profile
Syndax Pharmaceuticals Inc (SNDX) is a clinical-stage biopharmaceutical company focused on the development of cancer therapies. The company's lead product candidate is entinostat, an orally administered histone deacetylase (HDAC) inhibitor that has the potential to restore immune recognition of cancer cells and enhance the response to checkpoint inhibitors.
Entinostat is being evaluated in multiple clinical trials, including a phase 3 trial in combination with exemestane in advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, and a phase 2 trial in combination with pembrolizumab in patients with melanoma. Syndax is also developing SNDX-5613, a potent and selective inhibitor of the Menin-MLL interaction, which is being evaluated in a phase 1/2 trial for the treatment of relapsed/refractory acute leukemia.
Syndax has a strategic collaboration with Merck & Co. to evaluate the combination of entinostat with Merck's anti-PD-1 therapy, Keytruda, in multiple clinical trials. The company also has collaborations with several academic institutions, including the National Cancer Institute and the Parker Institute for Cancer Immunotherapy.
Syndax was founded in 2005 and is headquartered in Waltham, Massachusetts.
|
